New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery

Our study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silic...

Full description

Bibliographic Details
Main Authors: Angelo Spadaro, Marco Rao, Miriam Lorenti, Mario Rosario Romano, Antonio Augello, Chiara Maria Eandi, Chiara Bianca Maria Platania, Filippo Drago, Claudio Bucolo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00708/full
id doaj-8ca85b8fae51463bb78464f6141ecb51
record_format Article
spelling doaj-8ca85b8fae51463bb78464f6141ecb512020-11-25T03:33:18ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-05-011110.3389/fphar.2020.00708545969New Brilliant Blue G Derivative as Pharmacological Tool in Retinal SurgeryAngelo Spadaro0Marco Rao1Miriam Lorenti2Mario Rosario Romano3Antonio Augello4Chiara Maria Eandi5Chiara Maria Eandi6Chiara Bianca Maria Platania7Filippo Drago8Filippo Drago9Claudio Bucolo10Claudio Bucolo11Department of Drug Sciences, University of Catania, Catania, ItalyDepartment of Drug Sciences, University of Catania, Catania, ItalyDepartment of Drug Sciences, University of Catania, Catania, ItalyBiomedical Sciences, Humanitas University, Milano, ItalySection of Hygiene and Food of Animal Origin (SIAOA - UFCM), Department of Veterinary Prevention, Azienda Sanitaria Provinciale (ASP - CT), Catania, ItalyDepartment of Ophthalmology, University of Lausanne, Hôpital Ophtalmique Jules-Gonin, Lausanne, SwitzerlandDepartment of Surgical Science, University of Torino, Torino, ItalyDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, ItalyDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, ItalyCenter for Research in Ocular Pharmacology-CERFO, University of Catania, Catania, ItalyDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, ItalyCenter for Research in Ocular Pharmacology-CERFO, University of Catania, Catania, ItalyOur study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silico. Furthermore, an ex vivo model of vitreoretinal surgery was developed by using porcine eyes to assess the pharmacological profile of PBB, compared to commercial formulations based on BBG and methyl-BBG (Me-BBG). PBB showed a higher affinity for proteins (p < 0.05), compared to BBG and Me-BBG. In vitro and in silico studies demonstrated that the high selectivity of PBB could be related to high lipophilicity and binding affinity to fibronectin, the main component of the retinal internal limiting membrane (ILM). The PBB staining capabilities were evaluated in porcine eyes in comparison with BBG and Me-BBG. Forty microliters of each formulation were slowly placed over the retinal surface and removed after 30 s. After that, ILM peeling was carried out, and the retina collected. BBG, Me-BBG, and PBB quantification in ILM and retina tissues was carried out by HPLC analysis. PBB levels in the ILM were significantly (p < 0.05) higher compared to BBG and Me-BBG formulations. On the contrary, PBB showed a much lower (p < 0.05) distribution in retina (52 ng/mg tissue) compared to BBG and Me-BBG, in particular PBB levels were significantly (p < 0.05) lower. Therefore, the new synthetic Brilliant Blue derivative (PBB) showed a great ILM selectivity in comparison to underneath retinal layers. In conclusion, these findings had high translational impact with a tangible improving in ex vivo model of retinal surgery, suggesting a future use during surgical practice.https://www.frontiersin.org/article/10.3389/fphar.2020.00708/fullinner limiting membraneretinavitreoretinal surgeryBrilliant Blue Gpuckerdrug design
collection DOAJ
language English
format Article
sources DOAJ
author Angelo Spadaro
Marco Rao
Miriam Lorenti
Mario Rosario Romano
Antonio Augello
Chiara Maria Eandi
Chiara Maria Eandi
Chiara Bianca Maria Platania
Filippo Drago
Filippo Drago
Claudio Bucolo
Claudio Bucolo
spellingShingle Angelo Spadaro
Marco Rao
Miriam Lorenti
Mario Rosario Romano
Antonio Augello
Chiara Maria Eandi
Chiara Maria Eandi
Chiara Bianca Maria Platania
Filippo Drago
Filippo Drago
Claudio Bucolo
Claudio Bucolo
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
Frontiers in Pharmacology
inner limiting membrane
retina
vitreoretinal surgery
Brilliant Blue G
pucker
drug design
author_facet Angelo Spadaro
Marco Rao
Miriam Lorenti
Mario Rosario Romano
Antonio Augello
Chiara Maria Eandi
Chiara Maria Eandi
Chiara Bianca Maria Platania
Filippo Drago
Filippo Drago
Claudio Bucolo
Claudio Bucolo
author_sort Angelo Spadaro
title New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
title_short New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
title_full New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
title_fullStr New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
title_full_unstemmed New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
title_sort new brilliant blue g derivative as pharmacological tool in retinal surgery
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-05-01
description Our study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silico. Furthermore, an ex vivo model of vitreoretinal surgery was developed by using porcine eyes to assess the pharmacological profile of PBB, compared to commercial formulations based on BBG and methyl-BBG (Me-BBG). PBB showed a higher affinity for proteins (p < 0.05), compared to BBG and Me-BBG. In vitro and in silico studies demonstrated that the high selectivity of PBB could be related to high lipophilicity and binding affinity to fibronectin, the main component of the retinal internal limiting membrane (ILM). The PBB staining capabilities were evaluated in porcine eyes in comparison with BBG and Me-BBG. Forty microliters of each formulation were slowly placed over the retinal surface and removed after 30 s. After that, ILM peeling was carried out, and the retina collected. BBG, Me-BBG, and PBB quantification in ILM and retina tissues was carried out by HPLC analysis. PBB levels in the ILM were significantly (p < 0.05) higher compared to BBG and Me-BBG formulations. On the contrary, PBB showed a much lower (p < 0.05) distribution in retina (52 ng/mg tissue) compared to BBG and Me-BBG, in particular PBB levels were significantly (p < 0.05) lower. Therefore, the new synthetic Brilliant Blue derivative (PBB) showed a great ILM selectivity in comparison to underneath retinal layers. In conclusion, these findings had high translational impact with a tangible improving in ex vivo model of retinal surgery, suggesting a future use during surgical practice.
topic inner limiting membrane
retina
vitreoretinal surgery
Brilliant Blue G
pucker
drug design
url https://www.frontiersin.org/article/10.3389/fphar.2020.00708/full
work_keys_str_mv AT angelospadaro newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT marcorao newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT miriamlorenti newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT mariorosarioromano newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT antonioaugello newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT chiaramariaeandi newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT chiaramariaeandi newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT chiarabiancamariaplatania newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT filippodrago newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT filippodrago newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT claudiobucolo newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
AT claudiobucolo newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery
_version_ 1724563399414644736